An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed or Refractory, CD22- Positive, Follicular B-Cell Non Hodgkin’s Lymphoma

计划入组 0 人

A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN’S LYMPHOMA GRADES 1, 2 OR 3A

计划入组 10 人

The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

计划入组 60 人 · 首次发布于 2021 年 7 月 12 日

CAR-T CD19 cell therapy (mRNA technology, Non-Hodgkin’s Lymphoma)

Plerixafor(Mozobil, Plerixafor Accord)

C₂₈H₅₄N₈ · Rx

EBV+ Lymphoma (Geneius)

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

ASSOCIATION INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG)

Switzerland

Viridian Metals Inc

United States

Opdivo Demonstrates Superior Outcomes Compared to Adcetris in Hodgkin's Lymphoma Trial

Imugene Doses First Australian Patient in Phase 1b Trial of Azer-Cel for B-Cell Lymphoma

FDA Places Clinical Hold on Atara Biotherapeutics' Cell Therapy Programs Due to Manufacturing Concerns